Denosumab Trial Met Primary and All Secondary Endpoints by Significantly Delaying Time to First Skeletal Related Event and Significantly Reducing First-and-Subsequent Skeletal Related Events Compared to Zometa

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Wall Street Capital Funding.

Amgen's bone drug Prolia denosumab beat a competitor in an important Phase III prostate cancer trial, but investors remained cautious ahead of challenges elsewhere in the pipeline. by Trista Morrison

Amgen's bone drug Prolia denosumab beat a competitor in an important Phase III prostate cancer trial, but investors remained cautious ahead of challenges elsewhere in the pipeline. by Trista Morrison

Much of Amgen's AMGN future rests on its experimental bone drug denosumab, to be sold commercially as Prolia. The drug's had its ups and downs, but Amgen, the largest global biotech company, said on Monday that a pivotal third Phase 3 clinical trial pitting denosumab against Novartis's NVS Zometa showed...

Much of Amgen's AMGN future rests on its experimental bone drug denosumab, to be sold commercially as Prolia. The drug's had its ups and downs, but Amgen, the largest global biotech company, said on Monday that a pivotal third Phase 3 clinical trial pitting denosumab against Novartis's NVS Zometa showed...

Much of Amgen's (AMGN) future rests on its experimental bone drug denosumab, sold commercially as Prolia. The drug's had its ups and downs, but Amgen, the largest global biotech company, said on Monday that a pivotal third clinical trial pitting denosumab against Novartis's (NVS) Zometa showed that denosumab worked better.

Continue reading Amgen Says Its Drug Surpasses Rival in Preventing Fractures

Amgen Says Its Drug Surpasses Rival in Preventing Fractures originally appeared on DailyFinance on Tue, 09 Feb 2010 13:00:00.

Filed Under: Company News, Technology, Healthcare, Novartis, Amgen

Amgen Inc. (AMGN) received a boost recently when the company announced positive results from a pivotal head-to-head phase III study that was conducted with Amgen’s main pipeline candidate, denosumab. The study compared denosumab with Novartis’ (NVS) Zometa in the treatment of bone metastases in 1,901 patients with advanced prostate cancer. Amgen announced that denosumab met the [...]

(AMGN) Amgen Earns Positive Results From Phase III Drug Study

Amgen Inc. (AMGN) received a boost recently when the company announced positive results from a pivotal head-to-head phase III study that was conducted with Amgen’s main pipeline candidate, denosumab. The study compared denosumab with Novartis’ (NVS) Zometa in the treatment of bone metastases in 1,901 patients with advanced prostate cancer.  Amgen announced that denosumab met the ...

New York, feb 5th (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) are trading very close to calculated resistance at $59.42 with the current price action closing at just $57.53 placing the stock near levels that make it difficult to buy.

Amgen Inc. (NASDAQ:AMGN) develops, manufactures, and markets human therapeutics based on cel. Read More --

New York, jan 3rd (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) closed the trading session at $59.23 just above calculated resistance at $58.93 moving to what appears to be a new range, as this move will clearly raise the attention of momentum buyers.

Amgen Inc. (NASDAQ:AMGN) develops, manufactures, and markets human therapeu. Read More --

There is no better judge of a company's health and future prospects than the actions of owners and executives of publicly traded companies. That's why insider buying and selling is a critical piece of data for investors, both institutional and individual.[More...]

Amgen was put up one of the best ideas for 2010 by Blackrock’s Bob Dole this morning. At the same time, we seeing the following notes from the recent JP Morgan Healthcare Conference regarding Amgen (AMGN): Amgen Plans To Remain Active In Acquisitions, Licensing Amgen Ceo Sharer Says 2009 Eps Slightly Below Midpoint Forecast Amgen Ceo Believes Healthcare [...] Related posts:

1. Potash (POT) Cuts Guidance – Sales Soft, Outlook Dim
2. WYNN Resorts (WYNN) – Bet the Don’t Pass Line (SHORT)
3. Indicators We are Watching – Gold (GLD) Basing, Dollar Topping?

Companies featured in this segment: Pacific Gas & Electric Company (NYSE:PCG), Ameren Corporation (NYSE:AEE), Dow Chemical Company (NYSE:DOW), Corning Incorporated (NYSE:GLW), and Amgen Incorporated (NASDAQ:AMGN)

Companies featured in this segment: General Motors Corporation (NYSE:GM), Northfield Laboratories (NASDAQ:NFLD), Mitsui and Company Limited (NASDAQ:MITSY), Alkermes Incorporated (NASDAQ:ALKS), Shire plc (NASDAQ:SHPGY), ImmunoGen Incorporated (NASDAQ:IMGN), Schering-Plough (NYSE:SGP), BioMed Realty Trust Incorporated (NYSE:BMR), Amgen (NASDAQ:AMGN), Genzyme (NASDAQ:GENZ), Murphy Oil Corporation (NYSE:MUR), Centrica plc (OTC:CPYYY), Electric Power Development Company Limited (TYO:9513), and Electricite de France SA (EPA:EDF)

Companies featured in this segment: ABB (NYSE:ABB), Krishak Bharati Cooperative Limited, KBR (NYSE:KBR), Bayernoil Raffineriegesellschaft mbH, Jacobs Engineering Group (NYSE:JEC), Honeywell (NYSE:HON), Enel SpA (BIT:ENEL), Endesa SA (MCE:ELE), Acciona SA (MCE:ANA), Verenium Corporation (NASDAQ:VRNM), BP plc (NYSE:BP), Amgen Incorporated (NASDAQ:AMGN), Foster Wheeler Energy Limited, and Foster Wheeler AG (NASDAQ:FWLT).

Schaeffer's analyst Colleen S. King takes a look back at the major news of the day on Wall Street.